New hope for cerebral palsy movement issues: drug trial shows promise
NCT ID NCT05206513
First seen Apr 30, 2026 · Last updated May 21, 2026 · Updated 6 times
Summary
This study tested a drug called valbenazine to see if it can reduce jerky, uncontrolled movements (chorea) in children and adults with cerebral palsy. 86 participants received either the drug or a placebo for 14 weeks. The goal was to measure changes in movement severity using standard rating scales.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL PALSY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Neurocrine Clinical Site
San Diego, California, 92123, United States
-
Neurocrine Clinical Site
Aurora, Colorado, 80045, United States
-
Neurocrine Clinical Site
Stamford, Connecticut, 06905, United States
-
Neurocrine Clinical Site
Gulf Breeze, Florida, 32561, United States
-
Neurocrine Clinical Site
Miami, Florida, 33155, United States
-
Neurocrine Clinical Site
Orlando, Florida, 32806, United States
-
Neurocrine Clinical Site
Chicago, Illinois, 60611, United States
-
Neurocrine Clinical Site
Baltimore, Maryland, 21205, United States
-
Neurocrine Clinical Site
Boston, Massachusetts, 02115, United States
-
Neurocrine Clinical Site
Farmington Hills, Michigan, 48334, United States
-
Neurocrine Clinical Site
Saint Paul, Minnesota, 55101, United States
-
Neurocrine Clinical Site
New York, New York, 10003, United States
-
Neurocrine Clinical Site
Cincinnati, Ohio, 45229, United States
-
Neurocrine Clinical Site
Columbus, Ohio, 43205, United States
-
Neurocrine Clinical Site
Oklahoma City, Oklahoma, 73120, United States
-
Neurocrine Clinical Site
Portland, Oregon, 97239, United States
-
Neurocrine Clinical Site
Dallas, Texas, 75390-8857, United States
-
Neurocrine Clinical Site
Fort Worth, Texas, 76104, United States
-
Neurocrine Clinical Site
Houston, Texas, 77030, United States
-
Neurocrine Clinical Site
Buenos Aires, C1060AAF, Argentina
-
Neurocrine Clinical Site
Buenos Aires, C1425EFD, Argentina
-
Neurocrine Clinical Site
Brussels, 1200, Belgium
-
Neurocrine Clinical Site
Brasília, 70684-831, Brazil
-
Neurocrine Clinical Site
Curitiba, 80250-060, Brazil
-
Neurocrine Clinical Site
Porto Alegre, 90035-001, Brazil
-
Neurocrine Clinical Site
Porto Alegre, 90050-170, Brazil
-
Neurocrine Clinical Site
Ẕerifin, 7030000, Israel
-
Neurocrine Clinical Site
Calambrone, 56128, Italy
-
Neurocrine Clinical Site
Milan, 3. 20162, Italy
-
Neurocrine Clinical Site
Aguascalientes, Mexico
-
Neurocrine Clinical Site
Gdansk, 80-389, Poland
-
Neurocrine Clinical Site
Krakow, 30-539, Poland
-
Neurocrine Clinical Site
Oświęcim, 32-600, Poland
-
Neurocrine Clinical Site
Lisbon, 1169-045, Portugal
-
Neurocrine Clinical Site
Lisbon, 1649-035, Portugal
-
Neurocrine Clinical Site
Porto, 4050-651, Portugal
-
Neurocrine Clinical Site
Barcelona, 08038, Spain
-
Neurocrine Clinical Site
Madrid, 28006, Spain
Conditions
Explore the condition pages connected to this study.